Form 4: Cytokinetics Director Nancy Wysenski Acquires Shares Through Stock Retainer Program

Director Nancy Wysenski acquired 127 shares of Cytokinetics Inc. common stock through the Director Stock in Lieu of Cash Retainer Program.

Summary

• On January 2, 2025, Nancy Wysenski, a director of Cytokinetics Inc., acquired 127 shares of common stock.
• The acquisition was part of the Director Stock in Lieu of Cash Retainer Program.
• The price per share was $48.93.
• Following the transaction, Ms. Wysenski beneficially owns 23,115 shares of Cytokinetics Inc. common stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It reflects a routine transaction related to director compensation. It's neither overwhelmingly positive nor negative.

Positives

• The acquisition of shares by a director can be seen as a positive signal, indicating confidence in the company's future prospects.

Industry Context

Directors often receive stock as part of their compensation, aligning their interests with those of shareholders. This is a common practice in publicly traded companies.

Related Party Transactions

• The stock acquisition through the Director Stock in Lieu of Cash Retainer Program constitutes a related party transaction.

Stakeholder Impact

• The transaction has a minor positive impact on shareholders as it aligns the director's interests with theirs.

Key Dates